Built from Adma Biologics, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$13.19+4.2%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Company outlook: revenue of about $530M for Fiscal year 2026 — up 3.9% on a year earlier
The themes Adma Biologics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$48BA+
EXELExelixis, Inc.$17.3BA+
JAZZJazz Pharmaceuticals plc$15.9BA
HALOHalozyme Therapeutics, Inc.$11.6BA+
TECHBIO-Techne Corp$11.4BA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now AJust reported
From Adma Biologics's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$141.1M
+5.1% y/y
+13% q/q
Guided
—
No guide given
Actual
$0.22
+47% y/y
+38% q/q
Guided
—
No guide given
Actual
$67.8M
+33% y/y
+29% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade B+
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of Adma Biologics, Inc.’s grade history. The other 39 go back to November 2016.